We aim to evaluate the cost‐effectiveness of PCY testing by comparing two active cytology testing strategies of the intraoperative LPL (a guideline recommendation) and the preoperative PPL (a newly proposed testing) against the third strategy of ELNC (a common practice in rural regions) for GC patients with curative intent. The gene discussed is LPL; the disease is gastric cancer.